ROIV241220C19000
- 0.00
- 0.000.00%
Roivant Sciences Newsroom
Optimistic Outlook on Roivant Sciences Despite Namilumab Setback
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Roivant Sciences Ends Namilumab Study Due to Inefficacy
Roivant Sciences Unit Kinevant Sciences' Lung Disease Drug Fails in Mid-Stage Study
Express News | Roivant Sciences Shares Down 2.6% Premarket After Co's Lung Disease Drug Fails to Meet Main Goal in Mid-Stage Study
Express News | Roivant Sciences Ltd - Secondary Endpoints Also Fail to Show Treatment Benefit
Express News | Roivant Sciences Ltd - Kinevant to Discontinue Namilumab Development for Sarcoidosis
Express News | Roivant Announces Topline Results From Phase 2 Resolve-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Roivant Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Kinevant Sciences Announces Topline Results From Phase 2 RESOLVE-Lung Study of Namilumab in Chronic Active Pulmonary Sarcoidosis
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Insider Sale: President & COO of $ROIV (ROIV) Sells 100,000 Shares
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Roivant Sciences' (NASDAQ:ROIV) Shareholders Should Assess Earnings With Caution
Vivek Ramaswamy's Marching Orders: Cut Trillions for Trump -- WSJ
The Analyst Landscape: 5 Takes On Roivant Sciences
Roivant Sciences Analyst Ratings
Trump Taps Musk, Ramaswamy to Lead a 'Department of Government Efficiency.' He Called It 'The Manhattan Project of Our Time.' -- Barrons.com
Unusual Options Activity: GAP, SQ and Others Attract Market Bets, GAP V/OI Ratio Reaches 468.8